Moreover, we demonstrated that PD-L1 expression could be altered in human colorectal cancer by using DNA hypomethylating agents, providing more information about enhancing the response to the PD1/PD-L1 blockade. This evidence concerns the gene PDCD1 and colorectal cancer.